Clinical trialNCT05669430RecruitingPhase 1/PHASE2Interventional

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

SponsorGV20 TherapeuticsEnrollment365Cutaneous MelanomaEndometrial Carcinoma (EC)Non-Small Cell Lung CancerRefractory CancerSolid Tumor, AdultSquamous Head and Neck Carcinoma+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

the Angeles Clinic and Research Institute
Los Angeles, California, United States
Kristopher Wentzel, MD
Recruiting
Healthone Clinic Services Oncology - Hematology, Llc D/b/a Sarah Cannon Research Institute at Healthone
Denver, Colorado, United States
Jason Henry, MD
Not, yet, recruiting
Yale University
New Haven, Connecticut, United States
Patricia LoRusso, DO
Recruiting
Florida Cancer Specialists & Research Institute, Llc
Fort Myers, Florida, United States
Judy Wang, MD
Not, yet, recruiting
Community Health Network, Inc.
Indianapolis, Indiana, United States
Bert O'Neil, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Justin Gainor, MD
Recruiting
Barbara Ann Karmanos Cancer Hospital Dba Karmanos Cancer Center
Detroit, Michigan, United States
M. Najeeb Al Hallak, MD
Recruiting
Nyu Langone Health
New York, New York, United States
Janice Mehnert, MD
Recruiting
Oregon Health & Science University
Portland, Oregon, United States
Shivaani Kummar, MD
Recruiting
Verdi Oncology Tennessee, Scri Oncology Partners
Nashville, Tennessee, United States
Meredith Pelster, MD
Not, yet, recruiting
Oncology Consultants, P.A.
Houston, Texas, United States
Jose Peguero, MD
Recruiting
the University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
Aung Naing, MD
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Alexander Spira, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GV20-0251 →GV20-0251 and Pembrolizumab [KEYTRUDA®] →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 Mar 2023
Primary completion: 15 Dec 2026
Completion: 5 Sept 2027
Last update posted: 13 Feb 2025
Registered enrollment: 365
Registry id: NCT05669430

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.